CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair

Annals of Oncology

Volumn 28, Issue 7, 2017, Pages 1495-1507

  Shenoy, T R ^a   Boysen, G ^b,c   Wang, M Y ^d   Xu, Q Z ^d   Guo, W ^d   Koh, F M ^e   Wang, C ^a   Zhang, L Z ^d   Wang, Y ^a   Gil, V ^b   Aziz, S ^b   Christova, R ^b   Rodrigues, D N ^b,c   Crespo, M ^b,c   Rescigno, P ^c   Tunariu, N ^c   Riisnaes, R ^b,c   Zafeiriou, Z ^c   Flohr, P ^b,c   Yuan, W ^b   Knight, E ^b   Swain, A ^b   Ramalho Santos, M ^e   Xu, D Y ^d   de Bono, J ^b,c   Wu, H ^a,d   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d Peking University   (China)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chromatin remodeler CHD1; DDR; homologous recombination; non homologous end joining; PCa; synthetic lethality

Indexed keywords

CROSS LINKING REAGENT; FIZZY RELATED PROTEIN; FZR1 PROTEIN, HUMAN; FZR1 PROTEIN, MOUSE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TP53BP1 PROTEIN, HUMAN; TRP53BP1 PROTEIN, MOUSE; TUMOR SUPPRESSOR P53 BINDING PROTEIN 1;

ANIMAL; DEFICIENCY; DNA END JOINING REPAIR; DOSE RESPONSE; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; KNOCKOUT MOUSE; MALE; METABOLISM; PATHOLOGY; PHENOTYPE; PROSTATE TUMOR; PROTEIN STABILITY; RADIATION TOLERANCE; RECOMBINATION REPAIR; TIME FACTOR; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; CDH1 PROTEINS; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; DNA BREAKS, DOUBLE-STRANDED; DNA END-JOINING REPAIR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICE, KNOCKOUT; PHENOTYPE; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROSTATIC NEOPLASMS; PROTEIN STABILITY; RADIATION TOLERANCE; RECOMBINATIONAL DNA REPAIR; TIME FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR P53-BINDING PROTEIN 1;

EID: 85022042574     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx165     Document Type: Article

References (54)

1. Burkhardt, L., Fuchs, S., Krohn, A., et al. CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. Cancer Res 73 (2013), 2795–2805.
2. Liu, W., Lindberg, J., Sui, G., et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene 31 (2012), 3939–3948.
3. Baca, S.C., Prandi, D., Lawrence, M.S., et al. Punctuated evolution of prostate cancer genomes. Cell 153 (2013), 666–677.
4. Grasso, C.S., Wu, Y.M., Robinson, D.R., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 487 (2012), 239–243.
5. Huang, S., Gulzar, Z.G., Salari, K., et al. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 31 (2012), 4164–4170.
6. Gao, D., Vela, I., Sboner, A., et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159 (2014), 176–187.
7. Abeshouse, A., Ahn, J., Akbani, R., et al. The molecular taxonomy of primary prostate cancer. Cell 163 (2015), 1011–1025.
8. Boysen, G., Barbieri, C.E., Prandi, D., et al. SPOP mutation leads to genomic instability in prostate cancer. Elife, 4, 2015, e09207.
9. Baca, S.C., Prandi, D., Lawrence, M.S., et al. Punctuated evolution of prostate cancer genomes. Cell 153 (2013), 666–677.
10. Kari, V., Mansour, W.Y., Raul, S.K., et al. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness. EMBO Rep 17 (2016), 1609–1623.
11. Lusser, A., Urwin, D.L., Kadonaga, JT., Distinct activities of CHD1 and ACF in ATP-dependent chromatin assembly. Nat Struct Mol Biol 12 (2005), 160–166.
12. Konev, A.Y., Tribus, M., Park, S.Y., et al. CHD1 motor protein is required for deposition of histone variant h3.3 into chromatin in vivo. Science 317 (2007), 1087–1090.
13. Simic, R., Lindstrom, D.L., Tran, H.G., et al. Chromatin remodeling protein Chd1 interacts with transcription elongation factors and localizes to transcribed genes. EMBO J 22 (2003), 1846–1856.
14. Sims, R.J., Millhouse, S., Chen, C.F., et al. Recognition of trimethylated histone h3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing. Mol Cell 28 (2007), 665–676.
15. Lin, J.J., Lehmann, L.W., Bonora, G., et al. Mediator coordinates PIC assembly with recruitment of CHD1. Genes Dev 25 (2011), 2198–2209.
16. Gaspar-Maia, A., Alajem, A., Polesso, F., et al. Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 460 (2009), 863–U897.
17. Guzman-Ayala, M., Sachs, M., Koh, F.M., et al. Chd1 is essential for the high transcriptional output and rapid growth of the mouse epiblast. Development 142 (2015), 118–127.
18. Robinson, D., Van Allen, E.M., Wu, Y.M., et al. Integrative clinical genomics of advanced prostate cancer. Cell 161 (2015), 1215–1228.
19. Mateo, J., Carreira, S., Sandhu, S., et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373 (2015), 1697–1708.
20. Koh, F.M., Lizama, C.O., Wong, P., et al. Emergence of hematopoietic stem and progenitor cells involves a Chd1-dependent increase in total nascent transcription. Proc Natl Acad Sci USA 112 (2015), E1734–E1743.
21. Wu, X., Wu, J., Huang, J., et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 101 (2001), 61–69.
22. Pearl, L.H., Schierz, A.C., Ward, S.E., et al. Therapeutic opportunities within the DNA damage response. Nat Rev Cancer 15 (2015), 166–180.
23. Brown, C.E., Warren, S., Carcinoma of the prostate in irradiated parabiotic rats. Cancer Res 38 (1978), 159–162.
24. Taylor, B.S., Schultz, N., Hieronymus, H., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 18 (2010), 11–22.
25. Chapman, J.R., Taylor, M.R., Boulton, SJ., Playing the end game: DNA double-strand break repair pathway choice. Mol Cell 47 (2012), 497–510.
26. Pierce, A.J., Johnson, R.D., Thompson, L.H., Jasin, M., XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 13 (1999), 2633–2638.
27. Weinstock, D.M., Nakanishi, K., Helgadottir, H.R., Jasin, M., Assaying double-strand break repair pathway choice in mammalian cells using a targeted endonuclease or the RAG recombinase. Meth Enzymol 409 (2006), 524–540.
28. Polkinghorn, W.R., Parker, J.S., Lee, M.X., et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 3 (2013), 1245–1253.
29. Goodwin, J.F., Schiewer, M.J., Dean, J.L., et al. A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov 3 (2013), 1254–1271.
30. Tarish, F.L., Schultz, N., Tanoglidi, A., et al. Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair. Sci Transl Med, 7, 2015, 312re311.
31. Metzger, E., Willmann, D., McMillan, J., et al. Assembly of methylated KDM1A and CHD1 drives androgen receptor-dependent transcription and translocation. Nat Struct Mol Biol 23 (2016), 132–139.
32. Nelson, P.S., Clegg, N., Arnold, H., et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci USA 99 (2002), 11890–11895.
33. Hieronymus, H., Lamb, J., Ross, K.N., et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10 (2006), 321–330.
34. Kumar, A., Coleman, I., Morrissey, C., et al. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med 22 (2016), 369–378.
35. Kyprianou, N., Isaacs, JT., Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 122 (1988), 552–562.
36. Wang, S., Gao, J., Lei, Q., et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4 (2003), 209–221.
37. Mulholland, D.J., Tran, L.M., Li, Y., et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19 (2011), 792–804.
38. Bunting, S.F., Callen, E., Wong, N., et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141 (2010), 243–254.
39. Johnson, N., Johnson, S.F., Yao, W., et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci USA 110 (2013), 17041–17046.
40. Mallette, F.A., Richard, S., K48-linked ubiquitination and protein degradation regulate 53BP1 recruitment at DNA damage sites. Cell Res 22 (2012), 1221–1223.
41. Gonzalez-Suarez, I., Redwood, A.B., Grotsky, D.A., et al. A new pathway that regulates 53BP1 stability implicates cathepsin L and vitamin D in DNA repair. EMBO J 30 (2011), 3383–3396.
42. Hu, Y., Wang, C., Huang, K., et al. Regulation of 53BP1 protein stability by RNF8 and RNF168 is important for efficient DNA double-strand break repair. PLoS ONE, 9, 2014, e110522.
43. Han, X., Zhang, L., Chung, J., et al. UbcH7 regulates 53BP1 stability and DSB repair. Proc Natl Acad Sci USA 111 (2014), 17456–17461.
44. Bryant, H.E., Schultz, N., Thomas, H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005), 913–917.
45. Zhao, D., Lu, X., Wang, G., et al. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature 542 (2017), 484–488.
46. Francis, J.C., McCarthy, A., Thomsen, M.K., et al. Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis. PLoS Genet, 6, 2010, e1000995.
47. Maddison, L.A., Sutherland, B.W., Barrios, R.J., Greenberg, NM., Conditional deletion of Rb causes early stage prostate cancer. Cancer Res 64 (2004), 6018–6025.
48. Zhou, Z., Flesken-Nikitin, A., Corney, D.C., et al. Synergy of p53 and Rb deficiency in a conditional mouse model for metastatic prostate cancer. Cancer Res 66 (2006), 7889–7898.
49. Chen, Z., Trotman, L.C., Shaffer, D., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436 (2005), 725–730.
50. Bhatia-Gaur, R., Donjacour, A.A., Sciavolino, P.J., et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 13 (1999), 966–977.
51. Bunting, S.F., Nussenzweig, A., End-joining, translocations and cancer. Nat Rev Cancer 13 (2013), 443–454.
52. Al-Ubaidi, F.L., Schultz, N., Loseva, O., et al. Castration therapy results in decreased Ku70 levels in prostate cancer. Clin Cancer Res 19 (2013), 1547–1556.
53. Cunha, GR., The role of androgens in the epithelio-mesenchymal interactions involved in prostatic morphogenesis in embryonic mice. Anat Rec 175 (1973), 87–96.
54. Pierce, A.J., Jasin, M., Measuring recombination proficiency in mouse embryonic stem cells. Methods Mol Biol 291 (2005), 373–384.